Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine

Stefania Bulotta1, Marilena Celano1, Giuseppe Costante1,2

  • 1Department of Health Sciences, University "Magna Graecia" of Catanzaro, Campus "S. Venuta", 88100, Catanzaro, Italy.

Endocrine
|December 23, 2015
PubMed

Insights

Treating radioiodine-refractory thyroid cancer remains difficult. New molecular targets identified in differentiated thyroid tumors offer hope for developing innovative therapies against radioiodine-resistant thyroid cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Radioiodine-refractory thyroid cancer presents significant therapeutic challenges.
  • Differentiated thyroid tumors exhibit numerous genetic and epigenetic alterations.
  • These alterations represent potential targets for novel treatment strategies.

Purpose of the Study:

  • To review innovative treatment strategies for radioiodine-resistant thyroid cancers.
  • To highlight the potential of molecular targets in overcoming treatment resistance.

Main Methods:

  • Literature review of current research on thyroid cancer treatment.
  • Analysis of genetic and epigenetic alterations in differentiated thyroid tumors.
  • Exploration of emerging therapeutic approaches.

Main Results:

  • Identification of novel molecular targets in radioiodine-resistant thyroid cancer.
  • Overview of innovative strategies under investigation.
  • Potential for improved treatment outcomes.

Conclusions:

  • Targeting specific molecular alterations offers a promising avenue for treating radioiodine-resistant thyroid cancer.
  • Continued research into these novel strategies is crucial for advancing patient care.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K